CAMBRIDGE, Mass. — November 5, 2025 — Leads & Copy — Wave Life Sciences Ltd. (Nasdaq: WVE) is presenting preclinical data supporting WVE-007, a GalNAc-siRNA therapeutic for obesity, at ObesityWeek® in Atlanta on November 6. WVE-007 aims to reduce fat while preserving muscle mass by silencing INHBE mRNA and has shown promising results in preclinical models, including adipocyte shrinkage and improved insulin sensitivity. As an add-on to semaglutide, it doubled weight loss in mice and prevented weight regain. The INLIGHT clinical study evaluating WVE-007 is ongoing, with positive target engagement data announced last week.
According to Erik Ingelsson, MD, PhD, Chief Scientific Officer of Wave Life Sciences, GLP‑1 receptor agonists have transformed obesity care, but their impact is often limited by tolerability, frequent dosing, and loss of muscle mass. With a strong foundation in human genetics, WVE-007 is focused on healthy weight loss driven by fat loss, in particular visceral fat loss, while preserving muscle to make meaningful improvements in cardiometabolic health, which is ultimately the main objective of any obesity medication.
Key results from the company’s GalNAc-conjugated siRNA found that a single dose led to significant weight loss in mice; decreased infiltration of pro-inflammatory macrophages by up to 80%; and reduced fibrosis by 58%.
Wave expects multiple near-term clinical data updates from INLIGHT. An independent data monitoring committee supported dose expansion of Cohort 4 (600 mg) and dose escalation beyond that. Wave expects to deliver multiple near-term clinical data updates from INLIGHT, including body composition and body weight, beginning with three-month follow-up data from the Cohort 2 (240 mg) and data from Cohort 1 (75 mg) in the fourth quarter of 2025, six-month follow-up data from Cohort 2 (240 mg) and three-month follow-up data from Cohort 3 (400 mg) in the first quarter of 2026, and six-month follow-up data from Cohort 3 (400 mg) and three-month follow-up data from Cohort 4 (600 mg) in the second quarter of 2026.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
Source: Wave Life Sciences Ltd.
